The report covers emerging Endometriosis drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Endometriosis treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Endometriosis: An Overview
Endometriosis is a condition where patches of the endometrium appear in parts of the body other than the womb, such as the fallopian tubes, ovaries, or lungs. It is an idiopathic condition; possible explanations of causes include retrograde menstruation, the transformation of peritoneal cells, embryonic cell transformation, surgical scar implantation, endometrial cell transport, immune system disorder, etc.
Several factors augment disease propensity at greater risk of developing endometriosis, such as never giving birth, early menarche, late menopause, short menstrual cycles, genetic (mother, aunt or sister) with endometriosis, disorders of the reproductive tract, etc. The main complication of endometriosis is impaired fertility. Approximately one-third to one-half of women with endometriosis have difficulty getting pregnant. There is no lasting treatment for endometriosis, but available treatment options help in disease management, including surgical and nonsurgical treatments.
Nonsurgical endometriosis treatments include hormone therapy and pain management. Hormone therapy includes oral contraceptives, progestin, gonadotropin-releasing hormone antagonists, gonadotropin-releasing hormone agonists, etc. Moreover, pain management involves prescriptions of various pain medications, including nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen, which can be effective in managing endometriosis pain.
Various new therapies are in development with a focus on mentioned limitations of the currently approved drugs. Some of the most prominent ones include linzagolix (ObsEva SA), Ovarest (Enteris Biopharma), HMI-115 (Hope Medicine), VML-0501 (Viramal), others.
Endometriosis Market Key Facts
-
In 2022, the United States accounted for ~USD 1,200 million market size, expected to increase by the end of 2032.
-
As per DeleveInsight analysis, prescription analgesics (NSAIDs/ opioids) generated the highest revenue of ~USD 540 million in 2022.
-
In 2022, the total prevalent cases of endometriosis in the US were ~9,465,000.
-
In the US, the most endometriosis-affected people were found in the 18–29 age group, with ~4,993,000 cases in 2022.
-
The diagnosed prevalent cases of endometriosis by pain severity in the US were ~1,183,100 for mild, ~ 1,893,000 for moderate, and ~1,656,400 for severe in 2022.
-
Various key players currently leading the treatment landscape of endometriosis include Myovant Sciences, AbbVie, and others. Moreover, various key players are investigating their therapeutic candidates in the late phases of clinical development, including ObsEva, Enteris Biopharma, Hope Medicine, Ferring Pharmaceuticals, and others. The details of the country-wise and therapy-wise market size have been provided below.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Endometriosis pipeline therapies. It also thoroughly assesses the Endometriosis market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Endometriosis drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Endometriosis Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Endometriosis epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Endometriosis epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Endometriosis Epidemiology, Segmented as –
-
Total Prevalent Cases of Endometriosis in the 7MM (2019 to 2032)
-
Total Diagnosed Prevalent Cases of Endometriosis in the 7MM (2019 to 2032)
-
Age-specific Diagnosed Prevalent Cases of Endometriosis in the 7MM (2019 to 2032)
-
Diagnosed Prevalent Cases of Endometriosis by Pain Severity in the 7MM (2019 to 2032)
-
Total Treated Cases of Endometriosis in the 7MM (2019 to 2032)
Endometriosis Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Endometriosis market or expected to be launched during the study period. The analysis covers the Endometriosis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Endometriosis drugs based on their sale and market share.
The report also covers the Endometriosis pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Endometriosis companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Endometriosis Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/endometriosis-market
Endometriosis Therapeutics Analysis
There is currently no definitive cure for endometriosis, but there are therapies to reduce the pain, slow or prevent the growth of new lesions, and treat infertility. Depending on the age of the patient and the severity of the disease, the range of recommended treatments may differ.
The treatment paradigm of Endometriosis includes the use of simple pain relief medications, hormonal therapy, and surgery. The approved therapies for the management of endometriosis include Orilissa (AbbVie), Depo-subq Provera 104 (Pfizer), Lupron Depot (AbbVie), Zoladex (AstraZeneca), Synarel (Pfizer), Danocrine (Sanofi), etc.
Additionally, Orilissa is gonadotropin-releasing hormone (GnRH) receptor antagonist and Lupron Depot is gonadotropin-releasing hormone (GnRH) receptor agonist, approved for the management of moderate to severe pain associated with endometriosis while Depo-subQ provera 104 is a progestin that is indicated in females of reproductive age for prevention of pregnancy as well as management of endometriosis-associated pain. Another GnRH receptor antagonist Myfembree (Myovant Sciences and Pfizer), recently got approved by the US FDA in Severe Pain Associated With Endometriosis.
To further improve the treatment outlook, several major pharma and biotech companies are developing therapies for Endometriosis. Currently, ObsEva is leading the therapeutics market with its Endometriosis drug candidates in the most advanced stage of clinical development.
Endometriosis Companies Actively Working in the Therapeutics Market Include
AbbVie, Bayer, BCI Pharma, Camurus, Celmatix, Chugai Pharmaceutical, Dexa Medica Group, Enteris BioPharma, Ferring Pharmaceuticals, Forendo Pharma, Hope Medicine, Jiangsu HengRui Medicine Co., Ltd., Kissei Pharmaceuticals, Merck Sharp & Dohme Corp., Mitsubishi Tanabe Pharma Corporation, Myovant Sciences, Neurocrine Biosciences, Nippon Shinyaku, ObsEva SA, Organon, SWK, Tiumbio, Viramal, and many others.
Emerging and Marketed Endometriosis Therapies Covered in the Report Include:
-
Linzagolix: ObsEva
-
Relugolix: Myovant Sciences
-
ORIAHNN (elagolix/estradiol/ norethindrone acetate): AbbVie/Neurocrine Biosciences
-
OVAREST (leuprorelin oral): SWK/Enteris BioPharma
-
HMI-115: Bayer/Hope Medicine
-
TU2670 (NCE-403): Tiumbio
-
OG-6219: Organon
And Many More
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
https://www.delveinsight.com/sample-request/endometriosis-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Endometriosis Competitive Intelligence Analysis
4. Endometriosis Market Overview at a Glance
5. Endometriosis Disease Background and Overview
6. Endometriosis Patient Journey
7. Endometriosis Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Endometriosis Treatment Algorithm, Current Treatment, and Medical Practices
9. Endometriosis Unmet Needs
10. Key Endpoints of Endometriosis Treatment
11. Endometriosis Marketed Therapies
12. Endometriosis Emerging Drugs and Latest Therapeutic Advances
13. Endometriosis Seven Major Market Analysis
14. Attribute Analysis
15. Endometriosis Market Outlook (In US, EU5, and Japan)
16. Endometriosis Companies Active in the Market
17. Endometriosis Access and Reimbursement Overview
18. KOL Views on the Endometriosis Market
19. Endometriosis Market Drivers
20. Endometriosis Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/endometriosis-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Persistent Depressive Disorder Market
“Persistent Depressive Disorder Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Persistent Depressive Disorder market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Persistent Depressive Disorder market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/